Risedronate is the latest of the bisphosphonates to be used for the management of resorptive bone disease. Clinical improvements, assessed by the incidence of fracture and changes in bone mineral ...

report the first-year outcomes of a 2-year, multicenter, parallel group, randomized, controlled trial to evaluate the efficacy and safety of twice-monthly versus daily oral risedronate for ...

Dosages of risedronate (up to 30 mg/day) are generally well tolerated by patients with osteoporosis or Paget's disease. Adverse events were reported by 92.1 and 92.8% of risedronate 5 mg/day and ...